Shares of Exelixis (EXEL) are moving lower after the American Society of Clinical Oncology released an abstract on data for zanzalintinib alone or in combination with atezolizumab in patients with refractory metastatic colorectal cancer. As of May 6, 2024, 107 pateitns were enrolled. In the zanzalintinib plus atezolizumab and zanzalintinib groups, 39% and 51%, respectively, had an Eastern Cooperative Oncology Group Performance Status of one, patients had a median 2.5 and 3.0 prior lines of therapy, and 31% and 32% did not have liver metastases, respectively. With a median follow-up of 15 months across both arms, the median overall survival was 14.3 and 11.1 months for zanza plus atezo and zanza, respectively. Shares of Exelixis are down 7%, or $2.71, to $33.72 following the data.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target raised to $41 from $38 at Oppenheimer
- Exelixis price target raised to $42 from $38 at Truist
- Exelixis price target raised to $41 from $34 at JMP Securities
- Exelixis price target raised to $37 from $36 at Piper Sandler
- Exelixis reports preliminary FY24 revenue $2.165B, consensus $2.16B